Vitae Pharmaceuticals, Inc. offers clinical-stage biopharmaceutical products. The Company develops small molecule compounds that address medical needs such as chronic kidney disease, diabetes, atherosclerosis, and alzheimer’s diseases. Vitae Pharmaceuticals operates in the United States.
But recently, Vitae Pharmaceuticals , Inc. was acquired by Allergan PLC.
In India, the Pharmaceutical business of Vitae Pharmaceuticals Inc. is focused on Piperazine derivatives as liver X receptor modulators, Isoindoline inhibitors of ROR-gamma, Dihydropyrrolopyridine inhibitors of ROR-gamma, Liver X receptor modulators, Inhibitors of beta-secretase.
Vitae Pharmaceuticals Inc. filed patent application numbered 7636/DELNP/2014 that is titled LIVER X RECEPTOR MODULATORS. This patent application has been granted as Patent Number 316925.
The invention covers Chemical compound. Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.
During patent examination, the patent examiner raised objections under Section 3(d) of the Indian Patents Act, wherein the examiner stated that since the cited documents (D1-D2) disclose derivatives, structurally similar to the present compound formula I and the use of the compound is also for similar activity. Hence the present compounds are considered derivative of known compound as cited without any distinguishing improved efficacy with reference to the cited ones.
As a response to said objection, the applicant submits that there is no similarity and the same has been proven by diagrammatic representation and formula structure. The scientific structure and its differentiation has been explained.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
